Clinical Pharmacology & Therapeutics

Clinical Pharmacology & Therapeutics is the flagship journal of the American Society for Clinical Pharmacology and Therapeutics, published by Wiley, founded in 1960, and devoted to the nature, action, efficacy and evaluation of therapeutics, with a 2025 impact factor of 4.9（Clinical Pharmacology & Therapeutics）是美国临床药理学与治疗学学会的旗舰期刊，由 Wiley 出版，1960 年创刊，致力于治疗学的性质、作用、疗效与评价，2025 年影响因子为 4.9。

Scope

• It is an authoritative cross-disciplinary journal in experimental and clinical medicine devoted to advances in the nature, action, efficacy and evaluation of therapeutics该刊是实验与临床医学领域权威的跨学科期刊，致力于治疗学在性质、作用、疗效与评价方面的进展。
• Original articles cover translational medicine, predictive and personalised medicine, gene and cell therapy and pharmacogenomics原创论文覆盖转化医学、预测性与个体化医学、基因治疗与细胞治疗以及药物基因组学。
• Pharmacokinetics and pharmacodynamics, human investigation, clinical trials, pharmacovigilance, pharmacoepidemiology, pharmacometrics and population pharmacology are all included药代动力学与药效学、人体研究、临床试验、药物警戒、药物流行病学、药物计量学与群体药理学均在收录之列。
• Commentaries and Point-Counterpoint pieces offer clinical pharmacology perspectives on contemporary issues, while State of the Art reviews cover the latest advances评论与正反方栏目就当代议题提供临床药理学视角，而（State of the Art）综述则覆盖最新进展。
• The journal does not consider animal studies, and clinical trials must be publicly registered该刊不受理动物研究，临床试验必须公共注册。
• Article types open to direct submission are Articles, Clinical Trials and Letters to the Editor, while commentaries, reviews and State of the Art pieces are typically invited可直接投稿的类型为原创论文、临床试验与读者来信，评论、综述与（State of the Art）类多属约稿。

History

• It was founded by Walter Modell in 1957, with the first issue appearing in January 1960 as a bimonthly journal该刊 1957 年由 Walter Modell 发起创办，首期于 1960 年一月问世，当时为双月刊。^[1]
• It was first published by C. V. Mosby in St. Louis and was the official publication of the American Therapeutic Society, the forerunner of the ASCPT该刊最初由圣路易斯的 C. V. Mosby 出版，时为美国治疗学会的官方出版物，该学会即美国临床药理学与治疗学学会的前身。
• It became an official journal of the American Society for Pharmacology and Experimental Therapeutics in 1967 and remained linked to that society until 19831967 年该刊成为美国药理学与实验治疗学学会的官方期刊，与该学会的联系保持至 1983 年。^[2]
• Ownership passed from Mosby to Elsevier and then to the Nature Publishing Group before Wiley took over publication in 2015出版权先由 Mosby 归于 Elsevier，后转予 Nature Publishing Group，2015 年起由 Wiley 承继。
• It has been a monthly journal with two volumes of six issues each year and remains a subscription journal with a hybrid open access option该刊为月刊，每年两卷、每卷六期，仍为订阅期刊并设混合开放获取选项。

Editors

• The editor-in-chief is Karen Rowland Yeo of Certara UK, who took office in December 2025 and works on physiologically based pharmacokinetic modelling现任主编 Karen Rowland Yeo，任职于 Certara UK，2025 年十二月到任，研究基于生理的药代动力学建模。^[3]
• The deputy editor-in-chief is Karthik Venkatakrishnan of EMD Serono, and there are thirteen associate editors from Germany, Singapore, the United States, Israel, South Africa, Austria and the United Kingdom副主编为 EMD Serono 的 Karthik Venkatakrishnan，另有十三位副编辑，来自德国、新加坡、美国、以色列、南非、奥地利与英国。
• The board also includes a chief statistical consultant, a chief science advisor and two editors-in-training, and the founding editor W. Modell is listed as a founding editor编委会另设首席统计顾问、首席科学顾问与两名培训编辑，创刊主编 W. Modell 仍列名创刊编辑。
• Submissions are first screened by the relevant associate editor, and every paper considered for acceptance is reviewed by the whole editorial team before the editor-in-chief decides稿件由对口副编辑初筛，所有拟录用论文经全体编辑团队审议后由主编决定。
• Articles, clinical trials and letters may be submitted directly, and a seventy-five US dollar submission fee applies that is waived for invited authors原创论文、临床试验与来信可直接投稿，须缴七十五美元投稿费，受邀作者免缴。